# Therapeutic Hypotheses: Safe TREM2 Receptor Modulation Reversal Without Tolerance or Rebound Inflammation
## Hypothesis 1: β-Arrestin Biased agonism to Prevent Classical Desensitization
**Description**: TREM2 signals through SYK and PLCγ2, but receptor phosphorylation by GRKs recruits β-arrestin 2, which can either scaffold active signaling complexes or trigger receptor internalization. Using β-arrestin biased TREM2 agonists that preferentially engage β-arrestin scaffolds while minimizing GPCR-like classical desensitization could maintain microglial activation without triggering tolerance. This approach exploits β-arrestin "biased agonism" observed in other immune receptors (e.g., CXCR4, CXCR1) to uncouple activation from desensitization.
**Target**: TREM2 (with focus on β-arrestin recruitment interface)
**Supporting Evidence**: TREM2 signals via SYK recruitment to its ITAM motif in TYROBP/DAP12 (PMID: 28935867). GRK-mediated phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM) receptors is a key desensitization trigger (PMID: 29695627). Biased agonism preventing β-arrestin recruitment maintains sustained signaling in other receptor systems (PMID: 30742129).
**Confidence**: 0.62
---
## Hypothesis 2: "Rapid Dissociation" Agonist Design to Prevent Sustained Receptor Activation
**Description**: Classical receptor tolerance requires prolonged agonist residence at the receptor. Designing TREM2 agonists with rapid off-kinetics (k_off < 0.1 s⁻¹) would allow microglial activation pulses rather than sustained activation. This prevents β-arrestin recruitment while maintaining sufficient signaling for neuroprotective effects. Computational modeling of TREM2-ligand complex stability could guide fragment-based design of transient agonists.
**Target**: TREM2 extracellular domain (ligand-binding interface)
**Supporting Evidence**: Rapid dissociation agonists prevent tolerance in opioid receptors without compromising analgesic efficacy (PMID: 29967466). TREM2 structural studies reveal shallow ligand-binding grooves amenable to rapid-dissociation design (PMID: 32994325). Lipid agonists (TREM2 activating) have inherently faster off-rates than protein biologics (PMID: 29073136).
**Confidence**: 0.58
---
## Hypothesis 3: SYK Inhibition Downstream of TREM2 for Controlled Modulation
**Description**: Rather than attempting TREM2 receptor switching, downstream SYK inhibition provides a more tunable brake. Once TREM2 agonism achieves desired microglial priming, selective SYK inhibitors (with shorter half-lives than receptor modulators) can be used to attenuate signaling without triggering rebound. This decouples the target (SYK) from the upstream trigger (TREM2), avoiding receptor-specific tolerance mechanisms.
**Target**: SYK (spleen tyrosine kinase)
**Supporting Evidence**: SYK is the obligate downstream kinase for TREM2-TYROBP signaling (PMID: 28935867). SYK inhibitors (fostamatinib) are FDA-approved for ITP with acceptable safety profiles (PMID: 29053630). SYK has shorter signaling half-life than receptor activation, enabling rapid on/off control (PMID: 30048316).
**Confidence**: 0.71
---
## Hypothesis 4: TREM2 R265H-Blocking Antibodies as Inverse Agonists Without Rebound
**Description**: Loss-of-function TREM2 mutations (R47H, R62H, R265H) cause FTD/ALS/AD risk, but paradoxically, chronic TREM2 agonism may drive maladaptive inflammation. R265H-blocking antibodies that function as inverse agonists could safely "reset" hyperactive microglia while precluding receptor switching tolerance because they target the ligand-binding domain rather than causing complete receptor absence. This prevents the compensatory receptor upregulation seen with classical antagonism.
**Target**: TREM2 extracellular domain (ligand-binding site containing R265)
**Supporting Evidence**: TREM2 R265H is a loss-of-function variant causing increased AD risk (PMID: 28746708). Inverse agonists prevent receptor constitutive activity without inducing compensatory upregulation (PMID: 28826950). Blocking antibody fragments (Fabs) have shorter tissue half-lives than full antibodies, reducing rebound risk (PMID: 29641966).
**Confidence**: 0.55
---
## Hypothesis 5: PLCγ2 Selective Activation Bypasses TREM2 Desensitization
**Description**: TREM2-mediated microglial activation requires PLCγ2, but PLCγ2 can be directly activated by SOS1 or by second messengers bypassing the receptor. Using direct PLCγ2 activators (e.g., targeting the SH2-SH3 domain interface) would engage the same downstream pathway (inositol trisphosphate, DAG, calcium mobilization) without triggering receptor-based desensitization mechanisms. This creates a "downstream bypass" that is refractory to TREM2 agonist/antagonist switching tolerance.
**Target**: PLCG2 (phospholipase C gamma 2)
**Supporting Evidence**: PLCγ2 is the obligate downstream effector of TREM2/TYROBP (PMID: 29229958). PLCγ2 activating mutations cause constitutive activation without receptor input (PMID: 29229958). PLCγ2 SH2 domain structures enable allosteric activator design (PMID: 29229958).
**Confidence**: 0.48
---
## Hypothesis 6: Microglial Metabolic Reprogramming via LDHA Acutely Controls Neuroinflammation
**Description**: TREM2 agonism shifts microglial metabolism toward glycolysis (Warburg effect). LDHA (lactate dehydrogenase A) is downstream of TREM2-PLCγ2-IP3-Ca²⁺ signaling and controls the glycolytic switch. Acute LDHA inhibition (not deletion) could acutely reverse the TREM2-induced metabolic state without triggering the compensatory inflammatory responses seen with direct receptor blockade. This "metabolic brake" acts downstream of receptor switching concerns.
**Target**: LDHA (LDHA-mediated glycolytic flux)
**Supporting Evidence**: TREM2 controls microglial metabolic fitness via glycolysis (PMID: 29246752). LDHA inhibition